Center for Research in Security Prices, LLC

SuperAgers, individuals over 80 with memory performance of those in their 50s, defy aging norms. University of Chicago neurologist Emily Rogalski studies their unique brain structures and lifestyle factors, suggesting social engagement, mental exercise, and possibly genetics contribute to their cognitive resilience. The research aims to identify protective factors against cognitive decline, shifting focus from disease to positive aging trajectories.

Researchers developed a bioelectronic device using electrical stimulation to manage bacterial infections like Staphylococcus epidermidis, reducing biofilm formation and gene expression without antibiotics, with promising preclinical results on pig skin.

Corcept Therapeutics reports Q3 2024 revenue of $182.5M, up 48% YoY, and increases 2024 revenue guidance to $675-$700M. Net income per share is $0.41 (diluted), with cash and investments at $547.6M. The company plans to submit an NDA for relacorilant this quarter, supported by Phase 3 GRADIENT trial results.

An experimental electric bandage using imperceptible low-level electric current reduced Staphylococcus epidermidis by nearly 10 times, suggesting potential drug-free treatments for skin infections and wound healing.

States revive lawsuits to block mail-order abortion pills; FTC's new rule aims to curb fake consumer reviews; VP Kamala Harris proposes $25,000 down-payment assistance for first-time homebuyers.

Electroceutical patch reduced bacterial colonization by nearly tenfold in preclinical tests. Researchers discovered bacteria's excitability and developed a wearable device for biofilm infections without antibiotics. Potential for clinical use in chronic wounds and medical implants.

A UChicago team developed a hydrogel semiconductor with tissue-like properties, addressing the challenge of interfacing electronics with living tissue. The material, created through a solvent exchange process, combines semiconducting and hydrogel properties, improving bioelectronic device performance and reducing immune responses. This innovation has potential applications in medical devices and tissue engineering.

Oryzon Genomics reports financial results for Q3 2024, highlights PORTICO Phase IIb trial data for vafidemstat in BPD, FDA approval for PORTICO-2 Phase III trial, strengthened IP position for vafidemstat, and first cohort dosed in Phase Ib study of iadademstat in first-line AML. R&D expenses reduced by $5.1M.

Electroceutical patch reduces bacterial colonization by nearly tenfold in pig skin tests. Researchers developed a wearable device for biofilm infections without antibiotics, funded by the Bill & Melinda Gates Foundation, US Army Research Office, National Science Foundation, and National Institutes of Health.